GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunomedics Inc (NAS:IMMU) » Definitions » PS Ratio

Immunomedics (Immunomedics) PS Ratio : 976.22 (As of Apr. 25, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Immunomedics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Immunomedics's share price is $87.86. Immunomedics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 was $0.09. Hence, Immunomedics's PS Ratio for today is 976.22.

Warning Sign:

Immunomedics Inc stock PS Ratio (=974.78) is close to 1-year high of 974.78

The historical rank and industry rank for Immunomedics's PS Ratio or its related term are showing as below:

IMMU' s PS Ratio Range Over the Past 10 Years
Min: 353.44   Med: 3004   Max: 34780
Current: 974.78

During the past 13 years, Immunomedics's highest PS Ratio was 34780.00. The lowest was 353.44. And the median was 3004.00.

IMMU's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 8.98 vs IMMU: 974.78

Immunomedics's Revenue per Sharefor the three months ended in Jun. 2020 was $0.09. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 was $0.09.

Warning Sign:

Immunomedics Inc revenue per share has been in decline for the last 5 years.

During the past 3 years, the average Revenue per Share Growth Rate was -61.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was -50.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was -38.40% per year.

During the past 13 years, Immunomedics's highest 3-Year average Revenue per Share Growth Rate was 81.60% per year. The lowest was -61.10% per year. And the median was -2.30% per year.

Back to Basics: PS Ratio


Immunomedics PS Ratio Historical Data

The historical data trend for Immunomedics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunomedics PS Ratio Chart

Immunomedics Annual Data
Trend Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Dec19
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.56 68.24 294.33 1,632.67 10,580.00

Immunomedics Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 393.56

Competitive Comparison of Immunomedics's PS Ratio

For the Biotechnology subindustry, Immunomedics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunomedics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunomedics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Immunomedics's PS Ratio falls into.



Immunomedics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Immunomedics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=87.86/0.09
=976.22

Immunomedics's Share Price of today is $87.86.
Immunomedics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Immunomedics  (NAS:IMMU) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Immunomedics PS Ratio Related Terms

Thank you for viewing the detailed overview of Immunomedics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunomedics (Immunomedics) Business Description

Traded in Other Exchanges
N/A
Address
300 The American Road, Morris Plains, NJ, USA, 07950
Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in clinical and preclinical development. The company is marketing specific diagnostic imaging agents to detect bone infections in Europe, Canada, and Australia. The company has subsidiaries in the Netherlands and Germany to manage sales and clinical trials in Europe.
Executives
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Peter Barton Hutt director
Charles M Baum director C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Venbio Select Advisor Llc director, 10 percent owner, other: See Remarks 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh director, 10 percent owner, other: See Remarks C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Harout Semerjian director, officer: President and CEO 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950
Kurt J. Andrews officer: Chief Human Resources Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bryan Ball officer: Chief Quality Officer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Jared Freedberg officer: General Counsel 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Usama Malik officer: Chief Business Officer & CFO 300 THE AMERICAN WAY MORRIS PLAINS NJ 07950
Brendan Delaney officer: Chief Commerical Officer 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Lorettta M Itri officer: Chief Medical Officer